Inhalerx Ltd (IRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inhalerx Ltd (IRX) has a cash flow conversion efficiency ratio of -0.044x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$38.91K ≈ $27.53K USD) by net assets (AU$-877.11K ≈ $-620.61K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Inhalerx Ltd (IRX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Inhalerx Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Inhalerx Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Inhalerx Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inhalerx Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bio Green Med Solution, Inc.
NASDAQ:BGMS
|
-0.005x |
|
Whitemud Resources Inc
V:WMK
|
0.164x |
|
Henderson International Income Trust PLC
LSE:HINT
|
0.024x |
|
Biophytis S.A.
NASDAQ:BPTSY
|
0.000x |
|
ASIA Capital Group Public Company Limited
BK:ACAP
|
0.032x |
|
Smart Equity AG
HM:SE3
|
N/A |
|
Zeb Nickel Corp
V:ZBNI
|
0.003x |
|
Sulliden Minerals SA
TO:SMC
|
0.090x |
Annual Cash Flow Conversion Efficiency for Inhalerx Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Inhalerx Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Inhalerx Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$-63.97K ≈ $-45.26K |
AU$-368.77K ≈ $-260.93K |
5.765x | +295.55% |
| 2023-12-31 | AU$665.47K ≈ $470.86K |
AU$-1.96 Million ≈ $-1.39 Million |
-2.948x | -203.82% |
| 2022-12-31 | AU$1.90 Million ≈ $1.35 Million |
AU$-1.85 Million ≈ $-1.31 Million |
-0.970x | -126.23% |
| 2021-12-31 | AU$2.68 Million ≈ $1.89 Million |
AU$-1.15 Million ≈ $-812.69K |
-0.429x | +47.70% |
| 2020-12-31 | AU$1.32 Million ≈ $936.76K |
AU$-1.09 Million ≈ $-768.25K |
-0.820x | +85.05% |
| 2019-12-31 | AU$340.08K ≈ $240.63K |
AU$-1.87 Million ≈ $-1.32 Million |
-5.487x | -613.06% |
| 2018-12-31 | AU$2.68 Million ≈ $1.90 Million |
AU$-2.06 Million ≈ $-1.46 Million |
-0.770x | -35.45% |
| 2017-12-31 | AU$4.51 Million ≈ $3.19 Million |
AU$-2.56 Million ≈ $-1.81 Million |
-0.568x | -1717.88% |
| 2016-12-31 | AU$7.33 Million ≈ $5.19 Million |
AU$-229.03K ≈ $-162.05K |
-0.031x | -- |
About Inhalerx Ltd
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexali… Read more